Clinical Trials

Inclusion Criteria:

• Adult patients (≥ 18 years of age).
• Ability to obtain informed consent, either from patient or legally authorized representative (LAR).
• Diagnosis of AKI according to KDIGO definition [an increase in serum creatinine concentration of greater than or equal to 0.3 mg/dL within the first 48 hours of injury, a relative increase in serum creatinine of greater than or equal to 50% (1.5-fold from baseline) within the first 7 days of injury, or a reduction in urine output (< 0.5 mL/kg/h for more than 6 hours)].
• CRRT initiated for the first time during current ICU admission.
• Bicarbonate ≤ 22 mEq/L.
• Arterial pH between 7.05 and 7.25 (if an ABG is not available, venous pH must be between 7.00 and 7.20).

Exclusion Criteria:

• Pregnancy (women of child-bearing potential must have a negative pregnancy test).
• Diagnosis of End-Stage renal disease and receiving Hemodialysis or peritoneal dialysis prior to ICU admission (this information will be easily obtained by the nephrology team), or have received renal replacement therapy (either HD or CRRT) during the current hospital admission.
• Arterial pH < 7.05 or > 7.25 (if an ABG is not available, Venous pH  < 7.00 or > 7.20).
• Potassium level >6.0 mmol/L.
• Severe acute liver failure meeting any of the following criteria:
  • INR > 2;
  • AST > 500 U/L;
  • ALT > 500 U/L;
  • Bilirubin > 12 mg/dL.
• Previous enrollment in this study.